Zhen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhen Zhang has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Zhirong Yao
Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
12 shared publications Huaguo Li
Dermatology Center, Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China
5 shared publicationsYan Gu
Dermatology Center, Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China
5 shared publications- Hong Yu
Department of Dermatology, Xinhua Hospital, Shanghai, China
3 shared publications - Jianying Liang
Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China
3 shared publications - Ruoqu Wei
Dermatology Center, Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China
3 shared publications
Latest Publications
- 23 January 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (5) , 660-663
Primary cutaneous CD8 + aggressive epidermotropic cytotoxic T‐cell lymphoma in a 4‐year‐old girl
- 23 January 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (5) , 660-663
Primary cutaneous CD8 + aggressive epidermotropic cytotoxic T‐cell lymphoma in a 4‐year‐old girl
- Open Access
- 28 April 2023
- Published by Wiley
Investigating the causal effect between atopic dermatitis and allergic contact dermatitis: A two-sample Mendelian randomization study
Title: Investigating the causal effect between atopic dermatitis and allergic contact dermatitis: Atwo-sample Mendelian randomization studyAuthors: Zhenquan Xuan1,2,3, Jiawen Chen1,2,3, Zhen Zhang1,2,3, Yifeng Guo1,2,3, Hui Zhang1,2,3*, Zhirong Yao1,2
- 28 April 2023
- Published by Wiley
Open AccessInvestigating the causal effect between atopic dermatitis and allergic contact dermatitis: A two-sample Mendelian randomization study
Title: Investigating the causal effect between atopic dermatitis and allergic contact dermatitis: Atwo-sample Mendelian randomization studyAuthors: Zhenquan Xuan1,2,3, Jiawen Chen1,2,3, Zhen Zhang1,2,3, Yifeng Guo1,2,3, Hui Zhang1,2,3*, Zhirong Yao1,2
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 1) , S79-S83
Coexistence of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Dermatomyositis in a 12-Year-Old Boy
Wei R, et al. Ann Dermatol. 2023 May;35:e49. https://doi.org/10.5021/ad.20.310
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 1) , S79-S83
Open AccessCoexistence of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Dermatomyositis in a 12-Year-Old Boy
Wei R, et al. Ann Dermatol. 2023 May;35:e49. https://doi.org/10.5021/ad.20.310
- 7 November 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (3) , 401-406
Successful treatment with secukinumab of psoriasis‐like dermatitis in a patient with holocarboxylase synthetase deficiency
Holocarboxylase synthetase deficiency (HSD) is a rare autosomal recessive disorder of biotin metabolism. Typical manifestations include irreversible metabolic disorders and erythroderma‐like dermatitis. Most patients respond well to biotin supplementation. Psoriasis‐like phenotype associated with this disease has been rarely reported in the literature and experiences with the use of biologics in patients with HSD are still lacking. We reported a rare case of recurrent psoriasis‐like skin lesions in a 6‐year‐old child with HSD. The patient did not respond to initial therapy with high‐dose oral biotin. Immunofluorescence staining showed an increased number of interleukin (IL)‐17A+ cells in his skin lesions. Based on this finding, the patient was successfully treated with human anti‐IL‐17A monoclonal antibody (secukinumab). He did not report any side effects and remained healthy during the 2‐year follow‐up. We provide a comprehensive review of the reported cases of HSD with psoriasis‐like dermatitis to date. The psoriasis‐like phenotype of HSD is controversial in treatment and IL‐17A inhibitor is an alternative therapeutic option.
- 7 November 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (3) , 401-406
Successful treatment with secukinumab of psoriasis‐like dermatitis in a patient with holocarboxylase synthetase deficiency
Holocarboxylase synthetase deficiency (HSD) is a rare autosomal recessive disorder of biotin metabolism. Typical manifestations include irreversible metabolic disorders and erythroderma‐like dermatitis. Most patients respond well to biotin supplementation. Psoriasis‐like phenotype associated with this disease has been rarely reported in the literature and experiences with the use of biologics in patients with HSD are still lacking. We reported a rare case of recurrent psoriasis‐like skin lesions in a 6‐year‐old child with HSD. The patient did not respond to initial therapy with high‐dose oral biotin. Immunofluorescence staining showed an increased number of interleukin (IL)‐17A+ cells in his skin lesions. Based on this finding, the patient was successfully treated with human anti‐IL‐17A monoclonal antibody (secukinumab). He did not report any side effects and remained healthy during the 2‐year follow‐up. We provide a comprehensive review of the reported cases of HSD with psoriasis‐like dermatitis to date. The psoriasis‐like phenotype of HSD is controversial in treatment and IL‐17A inhibitor is an alternative therapeutic option.
- 23 February 2022
- Published by Elsevier in Cytotherapy
- Vol. 24 (5) , 526-533
Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma
- 23 February 2022
- Published by Elsevier in Cytotherapy
- Vol. 24 (5) , 526-533
Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma
- 7 January 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (4) , e15305
Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy
Click on the article title to read more.
- 7 January 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (4) , e15305
Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy
Click on the article title to read more.
- 4 January 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (4) , e15304
Majocchi's granuloma on the scalp of a 55‐year‐old female successfully treated with terbinafine
Click on the article title to read more.
- 4 January 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (4) , e15304
Majocchi's granuloma on the scalp of a 55‐year‐old female successfully treated with terbinafine
Click on the article title to read more.
- 1 February 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (2) , 223-227
Simvastatin ointment in the treatment of seven childhood diffuse plane xanthomas
Diffuse plane xanthomas (DPX) is a rare, chronic, metabolic skin disease which can seriously affect the appearance of the patients and result in psychological problems. Existing treatments are seriously limited. Our objective was to assess the efficacy of and tolerance to simvastatin ointment for the treatment of skin lesions in seven DPX patients. In this study, patients were treated twice daily on the right side of the lesions for 10 months with the 1% or 5% simvastatin ointment. Meanwhile, the left body was untreated as a contralateral controlled side. Efficacy was assessed via the change of rash and was further confirmed by histological study. For all seven participants, both the 1% and 5% simvastatin ointments were effective. The histological change in DPX showed significant decrease of foam cells in skin lesions. The immunohistochemical staining of CD68, macrophage scavenger receptor type 1, oxidized low-density lipoprotein receptor 1 and Oil Red O became obviously reduced after treatment. The test medicines were safe with only some skin-related side-effects. This is the first research reported on simvastatin ointment treatment in DPX. Our results are the first to suggest that simvastatin ointment is effective in improving skin lesions of DPX clinically and histopathologically.
- 1 February 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (2) , 223-227
Simvastatin ointment in the treatment of seven childhood diffuse plane xanthomas
Diffuse plane xanthomas (DPX) is a rare, chronic, metabolic skin disease which can seriously affect the appearance of the patients and result in psychological problems. Existing treatments are seriously limited. Our objective was to assess the efficacy of and tolerance to simvastatin ointment for the treatment of skin lesions in seven DPX patients. In this study, patients were treated twice daily on the right side of the lesions for 10 months with the 1% or 5% simvastatin ointment. Meanwhile, the left body was untreated as a contralateral controlled side. Efficacy was assessed via the change of rash and was further confirmed by histological study. For all seven participants, both the 1% and 5% simvastatin ointments were effective. The histological change in DPX showed significant decrease of foam cells in skin lesions. The immunohistochemical staining of CD68, macrophage scavenger receptor type 1, oxidized low-density lipoprotein receptor 1 and Oil Red O became obviously reduced after treatment. The test medicines were safe with only some skin-related side-effects. This is the first research reported on simvastatin ointment treatment in DPX. Our results are the first to suggest that simvastatin ointment is effective in improving skin lesions of DPX clinically and histopathologically.
- Open Access
- 16 January 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (3) , e1600
Netherton syndrome caused by compound heterozygous mutation, c.80A>G mutation in SPINK5 and large‐sized genomic deletion mutation, and successful treatment of intravenous immunoglobulin
Background: Netherton syndrome (NS) is an autosomal recessive disorder due to mutations in the SPINK5 gene. Here, we report the first case of NS caused by a large genomic deletion.Methods: We present the clinical data of a 3‐year‐old Chinese boy who was initially misdiagnosed with severe atopic dermatitis. Subsequently, the patient presented with typical ichthyosis linearis circumflexa and had representative hair shaft of trichorrhexis invaginate, which alerted the physician of the high possibility of NS. A genomic DNA sample was extracted from peripheral blood and whole‐exome sequencing (WES) was performed. Sanger sequencing and quantitative real‐time polymerase chain reaction (qRT‐PCR) were performed to verify the mutation and genomic deletion, respectively, in the pedigree.Results: WES revealed compound heterozygous mutations in SPINK5, including a c.80A>G mutation and a ~275 Kb‐sized genomic deletion (chr5:147443576‐147719312). The c.80A>G mutation was verified by Sanger sequencing in the pedigree. The father had the same heterozygous mutation; however, the mutation was absent in the proband's mother. The qRT‐PCR results identified a large deletion (chr5:147444834‐147445034) in SPINK5 in the proband and his mother. The eruptions improved remarkably after intravenous immunoglobulin (IVIG) therapy.Conclusions: This is the first observation of NS caused by a large deletion. Our findings have important implications for mutation screening and genetic counseling in NS. Our report also verifies and supports the safety and efficacy of IVIG therapy in patients with NS.
- 16 January 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (3) , e1600
Open AccessNetherton syndrome caused by compound heterozygous mutation, c.80A>G mutation in SPINK5 and large‐sized genomic deletion mutation, and successful treatment of intravenous immunoglobulin
Background: Netherton syndrome (NS) is an autosomal recessive disorder due to mutations in the SPINK5 gene. Here, we report the first case of NS caused by a large genomic deletion.Methods: We present the clinical data of a 3‐year‐old Chinese boy who was initially misdiagnosed with severe atopic dermatitis. Subsequently, the patient presented with typical ichthyosis linearis circumflexa and had representative hair shaft of trichorrhexis invaginate, which alerted the physician of the high possibility of NS. A genomic DNA sample was extracted from peripheral blood and whole‐exome sequencing (WES) was performed. Sanger sequencing and quantitative real‐time polymerase chain reaction (qRT‐PCR) were performed to verify the mutation and genomic deletion, respectively, in the pedigree.Results: WES revealed compound heterozygous mutations in SPINK5, including a c.80A>G mutation and a ~275 Kb‐sized genomic deletion (chr5:147443576‐147719312). The c.80A>G mutation was verified by Sanger sequencing in the pedigree. The father had the same heterozygous mutation; however, the mutation was absent in the proband's mother. The qRT‐PCR results identified a large deletion (chr5:147444834‐147445034) in SPINK5 in the proband and his mother. The eruptions improved remarkably after intravenous immunoglobulin (IVIG) therapy.Conclusions: This is the first observation of NS caused by a large deletion. Our findings have important implications for mutation screening and genetic counseling in NS. Our report also verifies and supports the safety and efficacy of IVIG therapy in patients with NS.